tradingkey.logo
tradingkey.logo
Search

Citius Oncology Inc

CTOR
Add to Watchlist
0.562USD
-0.016-2.77%
Close 07-24 16:00ETQuotes delayed by 15 min
52.27MMarket Cap
LossP/E TTM

CTOR Income Statement

You can find the annual or quarterly income statement of Citius Oncology Inc here for insights into the performance and operational efficiency of Citius Oncology Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
Total revenue
--1.67M
--3.94M
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
----
----
Revenue
--1.67M
--3.94M
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
----
----
Cost of revenue
--328.88K
--789.21K
----
----
----
----
----
----
----
----
----
----
----
----
----
Operating expenses
305.30%30.28M
43.81%9.20M
-76.35%4.71M
--4.94M
59.25%7.47M
39.52%6.39M
294.96%19.92M
68.43%4.69M
0.00%4.58M
3551.80%5.04M
--2.58M
--2.79M
--4.58M
--138.12K
--0.00
R&D expenses
-65.62%1.08M
-19.47%1.02M
-78.15%1.08M
--938.28K
132.73%3.14M
10.10%1.26M
327.60%4.93M
46.74%1.35M
0.00%1.15M
--1.15M
--1.24M
--919.31K
--1.15M
----
----
Depreciation, depletion, and amortization
--1.72M
--573.44K
----
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
----
----
Other operating expenses
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
Operating profit
-282.98%-28.61M
17.87%-5.25M
76.35%-4.71M
---4.94M
-59.25%-7.47M
-39.52%-6.39M
-294.96%-19.92M
-68.43%-4.69M
0.00%-4.58M
-3551.80%-5.04M
---2.58M
---2.79M
---4.58M
---138.12K
--0.00
Net non-operating interest income (expenses)
Non-operating interest income
--43.72K
--28.29K
--36.37K
----
----
----
----
-21.99%636.42K
-0.18%758.26K
159.11%1.28M
--579.40K
--815.85K
--759.65K
--493.02K
----
Non-operating interest expense
--33.03K
--45.84K
--57.28K
--160.75K
----
----
----
----
----
----
----
----
----
----
----
Special income (expenses)
--1.76M
----
----
----
----
----
----
----
----
----
----
----
--0.00
--25.91K
----
Other non-operating income (expenses)
----
----
----
----
----
----
---1.39M
----
----
----
----
----
----
----
----
Income before tax
-259.25%-26.84M
17.59%-5.27M
77.80%-4.73M
---5.11M
-59.25%-7.47M
-39.52%-6.39M
-322.61%-21.32M
-68.43%-4.69M
0.00%-4.58M
-1424.46%-5.04M
---2.58M
---2.79M
---4.58M
--380.81K
--0.00
Income tax
-187.50%-231.21K
0.00%264.24K
-54.13%264.24K
--264.24K
83.50%264.24K
83.50%264.24K
300.00%576.00K
0.00%144.00K
0.00%144.00K
--144.00K
--144.00K
--144.00K
--144.00K
----
----
Income after tax
-243.99%-26.61M
16.90%-5.53M
77.17%-5.00M
---5.37M
-59.97%-7.74M
-40.86%-6.66M
-321.98%-21.89M
-65.06%-4.84M
0.00%-4.73M
-1462.27%-5.19M
---2.73M
---2.93M
---4.73M
--380.81K
--0.00
Net income from continuous operations
-243.99%-26.61M
16.90%-5.53M
77.17%-5.00M
---5.37M
-59.97%-7.74M
-40.86%-6.66M
-321.98%-21.89M
-65.06%-4.84M
0.00%-4.73M
-1462.27%-5.19M
---2.73M
---2.93M
---4.73M
--380.81K
--0.00
Net income attributable to controlling interests
-243.99%-26.61M
16.90%-5.53M
77.17%-5.00M
---5.37M
-59.97%-7.74M
-40.86%-6.66M
-321.98%-21.89M
-65.06%-4.84M
0.00%-4.73M
-1462.27%-5.19M
---2.73M
---2.93M
---4.73M
--380.81K
--0.00
Net income attributable to common shareholders
-243.99%-26.61M
16.90%-5.53M
77.17%-5.00M
---5.37M
-59.97%-7.74M
-40.86%-6.66M
-321.98%-21.89M
-65.06%-4.84M
0.00%-4.73M
-1462.27%-5.19M
---2.73M
---2.93M
---4.73M
--380.81K
--0.00
Basic earnings per share
-146.06%-0.27
32.02%-0.06
80.19%-0.06
---0.08
-59.41%-0.11
-40.38%-0.09
-342.16%-0.32
-65.09%-0.07
0.00%-0.07
-272.23%-0.07
---0.04
---0.04
---0.07
--0.04
--0.00
Diluted earnings per share
-146.06%-0.27
32.02%-0.06
80.19%-0.06
---0.08
-59.41%-0.11
-40.38%-0.09
-342.16%-0.32
-65.09%-0.07
0.00%-0.07
-272.23%-0.07
---0.04
---0.04
---0.07
--0.04
--0.00
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Citius Oncology Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing CTOR stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Citius Oncology Inc's net income for the year?

Citius Oncology Inc posted -24.76M in net income for fiscal year 2025.

How much net income did Citius Oncology Inc post in the last quarter?

Citius Oncology Inc reported -26.61M in net income for the latest quarter。

What was Citius Oncology Inc's annual operating profit?

Citius Oncology Inc's operating income was -23.52M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.